Endonovo Therapeutics Inc (ENDV)

[Craig305]

I had posted the observation points on a previous post.
- company seems to be on a holding pattern lately. No news on any of the clinicals outside of the one at Univ. Of NM.
- The Chief Medical Officer is no longer listed on their website and no news about the departure?
- Endonovo is making high sales projections for Sofpulse.
- Company is controlling costs now? The dilution has slowed down to a trickle. Why the sudden stop? Especially after increasing the Authorized Shares?

If it's not for sale, merger play could be in the works. My guess would be Regenesis.
Endonovo has had 2 Tweets this year in which Regenesis' product was mentioned in a positive light.

On the flip side (just to show I'm being realistic and not a pumping cheerleader).....

You could see Makowka'a departure as a sign the liver clinical is not going to be successful and Endonovo will no longer work on that organ. Makowka's specialty was with the liver.

Maybe Endonovo is only going to focus on Sofpulse sales and the current study at NM since it was financed by the series C notes.

Maybe they are in a holding pattern for the FDA Innovation Challenge and hope to get publicity and financing from the potential PR. We will find out in November.

We will not see any significant revenue from Sofpulse until 2Q most likely.
The 1Q is when the sales team will begin their sales campaign.

Maybe we can see non toxic financing news come after FDA Challenge news, if successful.